Show simple item record

dc.contributor.authorLevy, Jason
dc.contributor.authorHopkins, Thomas
dc.contributor.authorMorris, Jonathan
dc.contributor.authorTran, Nam D.
dc.contributor.authorDavid, Elizabeth
dc.contributor.authorMassari, Francesco
dc.contributor.authorFarid, Hamed
dc.contributor.authorVogel, Alexander
dc.contributor.authorO'Connell, William G.
dc.contributor.authorSunenshine, Peter
dc.contributor.authorDixon, Robert
dc.contributor.authorGangi, Afshin
dc.contributor.authorvon der Hoh, Nicolas
dc.contributor.authorBagla, Sandeep
dc.date2022-08-11T08:10:49.000
dc.date.accessioned2022-08-23T17:21:15Z
dc.date.available2022-08-23T17:21:15Z
dc.date.issued2020-11-01
dc.date.submitted2020-12-17
dc.identifier.citation<p>Levy J, Hopkins T, Morris J, Tran ND, David E, Massari F, Farid H, Vogel A, O'Connell WG, Sunenshine P, Dixon R, Gangi A, von der Höh N, Bagla S. Radiofrequency Ablation for the Palliative Treatment of Bone Metastases: Outcomes from the Multicenter OsteoCool Tumor Ablation Post-Market Study (OPuS One Study) in 100 Patients. J Vasc Interv Radiol. 2020 Nov;31(11):1745-1752. doi: 10.1016/j.jvir.2020.07.014. PMID: 33129427. <a href="https://doi.org/10.1016/j.jvir.2020.07.014">Link to article on publisher's site</a></p>
dc.identifier.issn1051-0443 (Linking)
dc.identifier.doi10.1016/j.jvir.2020.07.014
dc.identifier.pmid33129427
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48478
dc.description.abstractPURPOSE: To evaluate the effectiveness of radiofrequency (RF) ablation as measured by change in worst pain score from baseline to 3 mo after RF ablation for the palliative treatment of painful bone metastases. MATERIALS AND METHODS: One hundred patients (mean age, 64.6 y) underwent RF ablation for metastatic bone disease and were followed up to 6 mo. Subjects' pain and quality of life were measured before RF ablation and postoperatively by using the Brief Pain Index and European Quality of Life questionnaires. Opioid agent use and device-, procedure-, and/or therapy-related adverse events (AEs) were collected. RESULTS: Eighty-seven patients were treated for tumors involving the thoracolumbar spine and 13 for tumors located in the pelvis and/or sacrum. All ablations were technically successful, and 97% were followed by cementoplasty. Mean worst pain score decreased from 8.2 +/- 1.7 at baseline to 3.5 +/- 3.2 at 6 mo (n = 22; P < 0.0001 for all visits). Subjects experienced significant improvement for all visits in average pain (P < .0001), pain interference (P < .0001), and quality of life (P < .003). Four AEs were reported, of which 2 resulted in hospitalization for pneumonia and respiratory failure. All 30 deaths reported during the study were attributed to the underlying malignancy and not related to the study procedure. CONCLUSIONS: Results from this study show rapid (within 3 d) and statistically significant pain improvement with sustained long-term relief through 6 mo in patients treated with RF ablation for metastatic bone disease.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=33129427&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rights© SIR, 2020. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectradiofrequency (RF) ablation
dc.subjectmetastatic bone disease
dc.subjectbone metastases
dc.subjectAnalytical, Diagnostic and Therapeutic Techniques and Equipment
dc.subjectMusculoskeletal Diseases
dc.subjectNeoplasms
dc.subjectRadiology
dc.titleRadiofrequency Ablation for the Palliative Treatment of Bone Metastases: Outcomes from the Multicenter OsteoCool Tumor Ablation Post-Market Study (OPuS One Study) in 100 Patients
dc.typeJournal Article
dc.source.journaltitleJournal of vascular and interventional radiology : JVIR
dc.source.volume31
dc.source.issue11
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1593&amp;context=radiology_pubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/radiology_pubs/581
dc.identifier.contextkey20660910
refterms.dateFOA2022-08-23T17:21:15Z
html.description.abstract<p>PURPOSE: To evaluate the effectiveness of radiofrequency (RF) ablation as measured by change in worst pain score from baseline to 3 mo after RF ablation for the palliative treatment of painful bone metastases.</p> <p>MATERIALS AND METHODS: One hundred patients (mean age, 64.6 y) underwent RF ablation for metastatic bone disease and were followed up to 6 mo. Subjects' pain and quality of life were measured before RF ablation and postoperatively by using the Brief Pain Index and European Quality of Life questionnaires. Opioid agent use and device-, procedure-, and/or therapy-related adverse events (AEs) were collected.</p> <p>RESULTS: Eighty-seven patients were treated for tumors involving the thoracolumbar spine and 13 for tumors located in the pelvis and/or sacrum. All ablations were technically successful, and 97% were followed by cementoplasty. Mean worst pain score decreased from 8.2 +/- 1.7 at baseline to 3.5 +/- 3.2 at 6 mo (n = 22; P < 0.0001 for all visits). Subjects experienced significant improvement for all visits in average pain (P < .0001), pain interference (P < .0001), and quality of life (P < .003). Four AEs were reported, of which 2 resulted in hospitalization for pneumonia and respiratory failure. All 30 deaths reported during the study were attributed to the underlying malignancy and not related to the study procedure.</p> <p>CONCLUSIONS: Results from this study show rapid (within 3 d) and statistically significant pain improvement with sustained long-term relief through 6 mo in patients treated with RF ablation for metastatic bone disease.</p>
dc.identifier.submissionpathradiology_pubs/581
dc.contributor.departmentDepartment of Radiology
dc.source.pages1745-1752


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
1_s2.0_S1051044320305911_main.pdf
Size:
641.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© SIR, 2020. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Except where otherwise noted, this item's license is described as © SIR, 2020. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)